Alnylam Pharmaceuticals Inc (ALNY)vsNeurosense Therapeutics Ltd (NRSN)
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
NRSN
Neurosense Therapeutics Ltd
$0.75
-3.85%
HEALTHCARE · Cap: $29.23M
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 12.6% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
NRSN
Avoid16
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2372.19
Current Price
$303.05
$2069.14 discount
Intrinsic value data unavailable for NRSN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : NRSN
The strongest argument for NRSN centers on Debt/Equity.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : NRSN
The primary concerns for NRSN are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a growth stock while NRSN is a value play — different risk/reward profiles.
NRSN carries more volatility with a beta of 1.54 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 16/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Neurosense Therapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Neurosense Therapeutics Ltd (NRSN) is a forward-thinking clinical-stage biotechnology firm dedicated to revolutionizing treatments for neurodegenerative diseases, with a primary emphasis on Parkinson's disease. Utilizing its proprietary development platform, the company is advancing a promising pipeline of innovative therapeutic candidates that are currently under pivotal clinical trials, aimed at addressing critical unmet medical needs within the neurology domain. Backed by an experienced management team and strategic partnerships, Neurosense is positioned to deliver groundbreaking therapies that enhance patient outcomes and solidify its competitive standing in the biopharmaceutical industry.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?